68,977 Shares in Neuronetics, Inc. (NASDAQ:STIM) Purchased by Kestra Private Wealth Services LLC

Key Points

• Kestra Private Wealth Services LLC has acquired 68,977 shares of Neuronetics, Inc. valued at approximately $254,000, signifying a new position in the company.
• Neuronetics reported a quarterly loss of ($0.21) EPS, missing analysts' estimates, while revenue reached $31.98 million, exceeding expectations.
• Insider trading activity saw EVP Stephen Furlong sell 193,460 shares, reducing his stake by 31.71%, now holding shares worth about $1.78 million.

Kestra Private Wealth Services LLC acquired a new position in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 68,977 shares of the company's stock, valued at approximately $254,000. Kestra Private Wealth Services LLC owned approximately 0.10% of Neuronetics at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in Neuronetics in the first quarter worth $25,000. Tradewinds LLC. increased its holdings in Neuronetics by 264.9% in the first quarter. Tradewinds LLC. now owns 72,977 shares of the company's stock valued at $269,000 after purchasing an additional 52,977 shares during the last quarter. KPP Advisory Services LLC bought a new stake in Neuronetics in the first quarter valued at about $37,000. HBK Sorce Advisory LLC bought a new stake in shares of Neuronetics in the first quarter worth about $142,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Neuronetics in the first quarter worth about $61,000. Institutional investors and hedge funds own 53.59% of the company's stock.

Neuronetics Trading Up 0.3%

Shares of Neuronetics stock traded up $0.02 during trading hours on Friday, hitting $4.41. The company's stock had a trading volume of 277,845 shares, compared to its average volume of 1,172,064. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.92. The stock has a 50 day moving average of $3.78 and a 200 day moving average of $3.91. The company has a market capitalization of $291.21 million, a PE ratio of -3.36 and a beta of 1.85. The company has a debt-to-equity ratio of 1.40, a current ratio of 2.44 and a quick ratio of 2.28.

Neuronetics (NASDAQ:STIM - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Neuronetics had a negative return on equity of 174.15% and a negative net margin of 53.67%. The business had revenue of $31.98 million during the quarter, compared to the consensus estimate of $29.07 million. Analysts predict that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Insider Activity

In related news, EVP Stephen Furlong sold 193,460 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the transaction, the executive vice president directly owned 416,593 shares in the company, valued at approximately $1,778,852.11. This trade represents a 31.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.70% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.